Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy

doi:10.4252/wjsc.v9.i3.45

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12262)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

598

WORD

375

HTML

6745

Figures (1-6)

271

Sum=7989

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

859

Download

1421

Sum=2280

Publishing Process of This Article

Item

Count

Browse

1056

Download

937

Sum=1993

Mar 26, 2017 (publication date) through Oct 3, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Mar 26, 2017; 9(3): 45-67
Published online Mar 26, 2017. doi: 10.4252/wjsc.v9.i3.45

Full Size Figure Download Figure

Figure 5 IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis. Kaplan-Meier survival plot representing IMT504 monotherapy vs antibiotic (cefepime) monotherapy vs control. IMT504 daily doses were started at day 5 after bacterial infection. Arrows indicate IMT504 treatment, which consisted of subcutaneous injections containing 50 g of IMT504 over 5 successive days. Experimental details described in Chahin et al[363].

Citation: Zorzopulos J, Opal SM, Hernando-Insúa A, Rodriguez JM, Elías F, Fló J, López RA, Chasseing NA, Lux-Lantos VA, Coronel MF, Franco R, Montaner AD, Horn DL. Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy. World J Stem Cells 2017; 9(3): 45-67
URL: https://www.wjgnet.com/1948-0210/full/v9/i3/45.htm
DOI: https://dx.doi.org/10.4252/wjsc.v9.i3.45